Skip to content

Hs-Troponin T Kinetics in Patients Treated With MCO Membranes Compared to High-flux, Low-flux Membranes and HDF

Hs-Troponin T Kinetics in Patients Treated With MCO Membranes Compared to High-flux, Low-flux Membranes and HDF

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05439681
Enrollment
22
Registered
2022-06-30
Start date
2022-08-12
Completion date
2022-12-24
Last updated
2023-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Troponin T

Keywords

hemodialysis, low-flux dialysis, high-flux dialysis, medium cut-off membrane

Brief summary

In this study, 24 prevalent hemodialysis patients will undergo four regular hemodialysis sessions during which four different treatments will be performed. * Treatment 1: MCO membrane (=medium cut off) * Treatment 2: low flux membrane * Treatment 3: high flux membrane * Treatment 4: HDF(=hemodiafiltration) treatment with high flux membrane So far, there is no data on cardiac bioenzyme levels during hemodialysis on the MCO membrane, thus, a acute elevation during hemodialysis might be mitigated by increased clearance.

Detailed description

Patients who are on hemodialysis will be included in this study. After obtaining informed consent, patients will be treated with four different hemodialysis sessions: * Treatment 1: MCO membrane (=medium cut off) * Treatment 2: low flux membrane * Treatment 3: high flux membrane * Treatment 4: HDF(=hemodiafiltration) treatment with high flux membrane The order of the treatment regimens with the different membranes will be randomized in four sequences (Williams design). Sequence 1: MCO, low flux, HDF, high flux Sequence 2: low flux, high flux, MCO, HDF Sequence 3: high flux, HDF, low flux, MCO Sequence 4: HDF, MCO, high flux, low flux Dialysis treatment will be standardized according to our clinic standard. Dialysis fluid temperature will be set to 1.0°C below the patient's body temperature, which will be assessed by auricular thermometers, to achieve maximal hemodynamic stability. Dialysis fluid composition will be standardized to calcium of 1.25mmol/L, bicarbonate of 30mmol/L, and a variable potassium and sodium concentration, depending on the patients' plasma potassium and sodium concentration. Ultrafiltration volume will be set according to the caretaking provider. Membranes used in the study will be FX CorDiax 10, 800 (Fresenius Medical Care, Bad Homburg vor der Höhe, Germany) and Theranova 400 (Baxter, Deerfield, Illinois, USA). We will perform the analysis only in mid-week dialysis due to the following reasons: First, hemodynamic stability is most often compromised during the first treatment of the week, due to the need of large volumes of ultrafiltration and, second, because we assume that troponin T levels reach a steady state 48 hours after the last dialysis session. Patients undergo their routine dialysis schedule, only the membrane will be changed. In each session, blood samples will be taken at the start of dialysis, after 1 and after 4 hours.

Interventions

medium cut off (MCO) membrane

DEVICEFX 10

low-flux membrane

DEVICEFX CorDiax 800

high-flux membrane

DEVICEHDF

hemodiafiltration

Sponsors

Medical University of Graz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Randomized controlled four-treatment, four-period crossover trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* minimum 18 years of age * End stage kidney disease patient undergoing hemodialysis * Written consent of the participant after being informed

Exclusion criteria

* No informed consent was obtained * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Troponin T - relative - 1 hour1 hour after start of hemodialysisRelative change from baseline (pre-treatment) to after 1 hour of hemodialysis in high sensitivity cardiac troponin T, assessed by Roche Elycsys Assay.

Secondary

MeasureTime frameDescription
Troponin T - relative - 4 hours4 hours after start of hemodialysisRelative change of high sensitivity cardiac troponin T from baseline to after completion of hemodialysis
Troponin I - relative - 1 hour and 4 hours1 hour and 4 hours after start of hemodialysisrelative change of high sensitivity cardiac troponin I from baseline to after 1 hour and after completion of hemodialysis
Troponin T - absolute - 1 hour and 4 hours1 hour and 4 hours after start of hemodialysisabsolute difference of high sensitivity cardiac troponin T from baseline to after 1 hour and after completion of hemodialysis
Troponin I - absolute - 1 hour and 4 hours1 hour and 4 hours after start of hemodialysisabsolute difference of high sensitivity cardiac troponin I from baseline to after 1 hour and after completion of hemodialysis

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026